Pharmacologic Therapy

Heart failure (HF) affects more than 5 million people and has an increasing incidence and cost burden. Patients note symptoms of dyspnea and fatigue that result in a decreased quality of life, which has not drastically improved over the past decades despite advances in therapies. The assessment of exercise capacity can provide information regarding patient diagnosis and prognosis, while doubling as a potential future therapy. clinically, there is acceptance that exercise is safe in hf and can have a positive impact on morbidity and quality of life, although evidence for improvement in mortality is still lacking. specific prescriptions for exercise training have not been developed because many variables and confounding factors have prevented research trials from demonstrating an ideal regimen. Physicians are becoming more aware of the indices and goals for hf patients in exercise testing and therapy to provide comprehensive cardiac care. it is further postulated that a combination of exercise training and pharmacologic therapy may eventually provide the most benefits to those suffering from hf.

Download Full-text

Effectiveness of Combining Behavioral and Pharmacologic Therapy for Complex Insomnia in Veterans With PTSD

Case Medical Research ◽

10.31525/ct1-nct03937713 ◽

2019 ◽

Author(s):

Keyword(s):

Pharmacologic Therapy

Download Full-text

Brexanolone: A Novel Drug for the Treatment of Postpartum Depression

Journal of Pharmacy Practice ◽

10.1177/0897190020979627 ◽

2020 ◽

pp. 089719002097962

Author(s):

Edna Patatanian ◽

David R. Nguyen

Keyword(s):

Adverse Effects ◽

Postpartum Depression ◽

English Language ◽

Neuronal Excitability ◽

Data Extraction ◽

Background Information ◽

Pharmacologic Therapy ◽

Loss Of Consciousness ◽

Efficacy And Safety ◽

Pubmed Search

Objectives: To review the pharmacology, efficacy, and safety of Brexanolone and define its role in the treatment of postpartum depression. Date Sources: A MEDLINE/PubMed search was conducted (1980-May 2020) using the following keywords: postpartum depression, antidepressants, pharmacologic therapy, drug therapy, and brexanolone to identify relevant articles. Study Selection/Data Extraction: Literature search was limited to human studies published in the English language. Phase I, II, and III studies evaluating the pharmacology, efficacy, safety of brexanolone for postpartum depression were included. Bibliographies of relevant articles evaluating postpartum depression and treatment were reviewed for additional citations and background information. Data Synthesis: Brexanolone is a soluble, proprietary, injectable formulation of allopregnanolone, a neuroactive steroid that modulates neuronal excitability. Allopregnanolone levels increase during pregnancy and decrease substantially after birth. These fluctuations have profound effects on anxiety and depression. Three clinical trials established the efficacy and safety of brexanolone in the treatment of postpartum depression. In all 3 trials, brexanolone had an acceptable safety profile and was well tolerated. The most common adverse effects were loss of consciousness, sedation, dry mouth, headache, dizziness, and flushing. Due to sudden loss of consciousness and excessive sedation, continuous pulse oximetry is recommended. Conclusion: Brexanolone has a novel mechanism of action and appears to be safe and effective for the treatment of moderate to severe postpartum depression. At present, high cost, serious adverse effects, and restricted access may limit its use in clinical practice.

Download Full-text

Esophagitis Dissecans Superficialis (EDS) Secondary to Hair Dye Ingestion: Case Report and Literature Review

Clinics and Practice ◽

10.3390/clinpract11020026 ◽

2021 ◽

Vol 11 (2) ◽

pp. 185-189

Author(s):

Eric Omar Then ◽

Tyler Grantham ◽

Michell Lopez ◽

Madhavi Reddy ◽

Vinaya Gaduputi

Keyword(s):

Case Report ◽

Literature Review ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Autoimmune Disorders ◽

Pharmacologic Therapy ◽

Esophageal Mucosa ◽

Hair Dye ◽

Esophageal Lesion ◽

Chemical Irritants

Esophagitis dissecans superficialis (EDS) is a rare and underdiagnosed esophageal lesion characterized by sloughing of the esophageal mucosa that has been associated with medications, various autoimmune disorders, and exposure to some chemical irritants. Anatomically, EDS is most commonly seen in the middle and distal thirds of the esophagus. When present, EDS is best treated by discontinuing the offending agent and initiating pharmacologic therapy with proton pump inhibitors. Steroids may also be effective if the etiology is autoimmune in nature. Our case highlights a 65-year-old female diagnosed with EDS after incidental ingestion of hair dye containing resorcinol and para-phenylenediamine (PPD).

Download Full-text

COPD Guidelines in the Asia-Pacific Regions: Similarities and Differences

Diagnostics ◽

10.3390/diagnostics11071153 ◽

2021 ◽

Vol 11 (7) ◽

pp. 1153

Author(s):

Shih-Lung Cheng ◽

Ching-Hsiung Lin

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Global Strategy ◽

Airflow Limitation ◽

Asia Pacific ◽

Pharmacologic Therapy ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Country Level ◽

Similarities And Differences

Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease that is associated with significant morbidity and mortality, giving rise to an enormous social and economic burden. The Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) report is one of the most frequently used documents for managing COPD patients worldwide. A survey was conducted across country-level members of Asia-Pacific Society of Respiratory (APSR) for collecting an updated version of local COPD guidelines, which were implemented in each country. This is the first report to summarize the similarities and differences among the COPD guidelines across the Asia-Pacific region. The degree of airflow limitation, assessment of COPD severity, management, and pharmacologic therapy of stable COPD will be reviewed in this report.

Download Full-text